摘要
2020年发布的中国和欧洲青光眼指南,相继推荐了前列腺素衍生物(PGAs)在青光眼局部降眼压治疗中的临床应用,并将PGAs作为原发性开角型青光眼的一线用药。为了加强对新指南的认识,推动PGAs在各级医院的规范化应用,笔者在2021年1月浙江杭州举办的青光眼西湖论坛期间,同青光眼领域众多专家召开讨论会,结合国内外大量文献分析了临床实践中PGAs用药存在的问题,围绕PGAs降眼压机制研究现状及特殊情况下的用药建议进行了学术探讨。
Nowadays,prostaglandin analogues(PGAs)have been increasingly used in lowering intraocular pressure,and recommended as the first-line drugs for primary open angle glaucoma(POAG)in the latest glaucoma guidelines.In order to enhance the understanding of new guidelines and promote the standardized application of PGAs,experts held a panel discussion during the West Lake Glaucoma Conference in Hangzhou,Zhejiang Province,in January 2021,analyzing the issues in PGAs clinical practice with a large number of references.In that meeting,opinions and recommendations for PGAs medication were put forward on the basis of the research progress of the mechanism for lowering intracular pressure,as well as PGAs clinical trials in special cases.
作者
杨雨美
张琪
刘鑫
陈敏
梁远波
王凯军
Yumei Yang;Qi Zhang;Xin Liu;Min Chen;Yuanbo Liang;Kaijun Wang(Eye Center,the Second Affiliated Hospital,School of Medicine,Zhejiang University,Hangzhou 310009,China;Department of Ophthalmology,Shaoxing Shangyu People's Hospital,Shaoxing 312300,China;Eye Hospital,Wenzhou Medical University,Wenzhou 325027,China)
出处
《中华眼视光学与视觉科学杂志》
CAS
CSCD
2023年第3期161-166,共6页
Chinese Journal Of Optometry Ophthalmology And Visual Science
关键词
青光眼
前列腺素衍生物
眼压
glaucoma
prostaglandin analogues
intraocular pressure
